Tradestie Institutional Equity Comparison Engine

LYRA vs OBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OBIO Overall Edge

OBIO Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
LYRA N/M vs OBIO N/M Fwd P/E
Growth & Margin Winner OBIO
Op Margin -25032.0% vs -195.4% ยท YoY -87.2% vs -89.4%
Momentum & Technical Winner OBIO
1Y -94.3% vs +78.2% ยท 52W Pos 1% vs 89%
Options & Structure Winner OBIO
UNCLASSIFIED (N/A IV) vs BREAKOUT (<1st %ile IV)
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.02
-1.4% 1D
Market Cap $570.6M
1M Return +24.25%
1Y Return +78.17%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 62.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LYRA -94.34% OBIO +78.17% Spread: +102.62 pp (OBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LYRA Revenue OBIO Revenue LYRA Op. Margin OBIO Op. Margin Margin Edge
FY2021 $0M N/A -15303.5% N/A LYRA
FY2022 $0M $0M -4131.0% -924.3% OBIO
FY2023 $0M $0M -4308.1% -1866.2% OBIO
FY2024 $0M $0M -6280.8% -2437.5% OBIO
FY2025 $0M $30M -7794.5% -154.7% OBIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LYRA (3) vs OBIO (5)
Institutional Metric LYRA OBIO Criterion Row Winner
Market Capitalization Scale $2.3M $570.6M Larger Scale OBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -87.2% -89.4% Higher Growth LYRA
Operating Margin (TTM) Profitability -25032.0% -195.4% Higher Margin OBIO
Net Profit Margin Profitability 0.0% -182.5% Higher Margin LYRA
Return on Equity (ROE) Capital Efficiency -404.5% -182.3% Higher ROE OBIO
52-Week Range Position Momentum 1% ($0โ€“$38) 89% ($3โ€“$7) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 0.33ฮฒ ยท 248% Vol 1.15ฮฒ ยท 80% Vol Lower Realized Risk OBIO
Unified Institutional Score Composite Signal 52.2 / 100 (HOLD) 42.9 / 100 (HOLD) Higher Composite LYRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LYRA vs OBIO Buy Guide
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OBIO BREAKOUT
33d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LYRA nor OBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.